Edition:
India

LivaNova PLC (LIVN.OQ)

LIVN.OQ on NASDAQ Stock Exchange Global Select Market

86.10USD
2:28am IST
Change (% chg)

$0.32 (+0.37%)
Prev Close
$85.78
Open
$85.81
Day's High
$86.19
Day's Low
$85.31
Volume
64,626
Avg. Vol
145,912
52-wk High
$86.19
52-wk Low
$42.99

Chart for

About

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

BRIEF-Microport Scientific's unit buys CRM business from Livanova

* ‍Unit buys CRM business for initial consideration of US$190 million​ from Livanova PLC Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

20 Nov 2017

BRIEF-LivaNova Plc reports ‍Q3 diluted earnings per share were $0.57​

* LivaNova Plc - ‍Q3 2017 diluted earnings per share were $0.57​

02 Nov 2017

BRIEF-Livanova receives FDA approval for Vagus Nerve Stimulation Therapy system​

* Livanova receives FDA approvals for SenTiva device and next-generation VNS therapy programming system for treatment of epilepsy

09 Oct 2017

BRIEF-Livanova and Microport announce approval of Rega pacemakers by China FDA

* Livanova and Microport announce the approval of Rega pacemakers by the China Food and Drug Administration

27 Sep 2017

BRIEF-Livanova announces U.S. Launch of Optiflow Arterial Cannulae Family

* Says ‍received FDA 510(k) clearance for U.S. Market launch of its Optiflow Arterial Cannulae Family​ Source text for Eikon: Further company coverage:

25 Sep 2017

BRIEF-LivaNova ‍expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term​

* LivaNova Plc - ‍Expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term​

15 Sep 2017

BRIEF-Livanova ‍Q2 adjusted EPS $1.01​

* Q2 earnings per share view $0.82, revenue view $315.6 million -- Thomson Reuters I/B/E/S

09 Aug 2017

BRIEF-VNS Therapy receives FDA approval for expanded MRI Labeling

* VNS Therapy receives FDA approval for expanded mri labeling

21 Jun 2017

Earnings vs. Estimates

No consensus analysis data available.